Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: A case report. [PDF]
J Int Med ResAl Adel F +3 more
europepmc +1 more source
Anti-VEGF therapy for posterior segment disorders: The story so far…. [PDF]
Indian J OphthalmolChawla R.
europepmc +1 more source
Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. [PDF]
CureusBousamri A +6 more
europepmc +1 more source
Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]
Front Public HealthHamida JA +7 more
europepmc +1 more source
Exudative retinopathy from retinal vasoproliferative tumor refractory to aflibercept treated with faricimab-svoa. [PDF]
Am J Ophthalmol Case RepKarthik N +4 more
europepmc +1 more source
From bench to bed: The evolution of anti-vascular endothelial growth factor therapies. [PDF]
Indian J OphthalmolSen A, Kohli G, Agarwal A, Chauhan R.
europepmc +1 more source
Anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. [PDF]
Indian J OphthalmolGiridhar A, Lekha T, Chandran K.
europepmc +1 more source
One-Year Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in Japan: A Multicenter Retrospective Study. [PDF]
Clin OphthalmolMizuma R +6 more
europepmc +1 more source
Different aflibercept regimens for wet age-related macular degeneration: A systematic review and network meta-analysis. [PDF]
J Chin Med AssocChen YS +5 more
europepmc +1 more source
New Clinical Trials and Therapeutic Advances with Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Durability-Oriented Comparative Perspective. [PDF]
BiomedicinesMenna F +5 more
europepmc +1 more source